Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New Press Release - Theralase(R) Announces Appointment of New Independent Director

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Jun 06, 2023 7:42am

213 Views

Post# 35481885

RE:New Press Release - Theralase(R) Announces Appointment of New Independent Director

This nomination is another step announcing an onward and upward transformative movement over time. Clearly, others steps are coming.

Interesting profile:

- extensive big pharma exposure
- served, for over a decade, in global and regional leadership roles at Amgen, Sanofi, GlaxoSmithKline and AstraZeneca, in the United States, Europe, United Kingdom, Middle East and North Africa,
- specialized executive master's degree in strategy and management from ESSEC Business School in Paris, a master's degree in international policy and health economics from the London School of Economics, a corporate governance certification from Columbia Business School and finance certification from Harvard Business School,
- board of directors of Hepion Pharmaceuticals; a US public biotech (NASDAQ: HEPA),
- employed in executive and non-executive roles for: Cytovia Therapeutics, Steba Biotech and Immune Pharmaceuticals,

Based on this latest interim clinical data, the Company is commencing to actively explore international partnering, licensing and distribution opportunities for our cancer targeting PDC, Ruvidar™